USA. FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
USA. FDA approves new dosage strength of buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
Agency is taking additional steps to advance the development of new FDA-approved treatments for opioid dependence and encourage their more widespread use.
The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film, which is also approved in both brand name and generic versions and in various strengths. (FDA - U.S. Food and Drug Administration, 07.09.2018)
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm619864.htm